A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Our body's own defense system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumor ...

Many different cancer treatments work to directly target the tumor or the cells around it. The immediate goal is to mitigate ...

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

Emerging research highlights how vitamin D boosts immunity and reduces colorectal cancer (CRC) risk by regulating ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...